{
    "nct_id": "NCT03492671",
    "official_title": "A Phase II Trial of Pre-operative Chemotherapy (With Gemcitabine and Nab- Paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients With Resectable Pancreatic Adenocarcinoma",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patient has borderline resectable or metastatic disease.\n* History of malignancy in the last 5 years other than in situ cancer or basal or squamous cell skin cancer or malignancies cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years.\n* Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.",
    "miscellaneous_criteria": "Inclusion Criteria (all criteria must apply):\n\n* Cytologic or histologic proof of adenocarcinoma of the pancreas.\n* Localized, potentially resectable tumors.\n* Greater or equal to 18 years of age.\n* ECOG performance status of 0 or 1.\n* Adequate hematologic, renal and hepatic function as defined by:\n* ANC greater or equal to 1,500 cells/mm3\n* Platelets greater or equal to 100,000 cells/mm3\n* Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)\n* Serum creatinine ≤ 2 x ULN • ALT ≤ 5 x ULN\n* AST ≤ 5 x ULN\n* No history of prior therapy for pancreatic cancer.\n* No history of active infection requiring IV antibiotics at the start of study treatment\n* Non-pregnant and non-breast-feeding."
}